MHRA-102190-PIP01-25

Key Facts

Active Substance
Active Substance:
  • RANIBIZUMAB
Invented Name
  • Susvimo
  • Susvimo
  • Susvimo
  • Susvimo
  • Susvimo
  • Susvimo
  • Susvimo
  • Susvimo
  • Susvimo
PIP Number MHRA-102190-PIP01-25
Pharmaceutical form(s)
Pharmaceutical form(s):
  • Solution for injection
Therapeutic area
Therapeutic area:
  • Ophthamology
Conditions / Indications
Conditions / Indications:
  • Treatment of age-related macular degeneration and diabetic macular oedema
Route(s) of administration
Route(s) of administration:
  • Intravitreal use
PIP applicant
  • Roche Products Limited
  • Country United Kingdom
  • Tel 01707368671
  • Email uk.dra@roche.com
Decision Type
Decision Type
W: decision granting a waiver in all age groups for the listed condition(s).
Compliance Check
Compliance Check
No
Compliance Check Decision Date
Compliance Check Procedure Number

Decision Document

Decision Document Decision Document on a Paediatric Investigation Plan (PIP):RANIBIZUMAB.pdf
Published Date 18/12/2025